This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HCA Healthcare Trades at a Premium: Buy, Hold, or Avoid the Stock?
by Kaibalya Pravo Dey
HCA trades above peers on valuation, backed by strong cash flow and buybacks, but weighed by debt and sector headwinds.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tenet Healthcare Jumps 46% YTD & Trades Cheap: Should You Buy Now?
by Kaibalya Pravo Dey
THC's 46% YTD surge, upgraded outlook, and discounted valuation highlight its strong growth potential.
Here's Why HCA Healthcare (HCA) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Pediatrix Medical Refills Its Buyback Prescription With $250M Dose
by Kaibalya Pravo Dey
MD launches a $250M buyback, fueled by stronger cash flow, leaner operations and robust 2025 profit outlook.
Here's Why HCA Healthcare (HCA) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
If You Invested $1000 in HCA Healthcare a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Top Stock Reports for Broadcom, Philip Morris & Novo Nordisk
by Mark Vickery
Broadcom, Philip Morris, and Novo Nordisk face contrasting outlooks as AI growth, smoke-free expansion, and obesity drug hurdles shape performance.
Why HCA Healthcare (HCA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why HCA Healthcare (HCA) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pediatrix Medical's Q2 Earnings Beat on Strong Patient Volumes
by Zacks Equity Research
MD's Q2 earnings benefit from higher patient volumes and a declining expense level. It now projects 2025 adjusted EBITDA within $245-$255 million, up from the prior view of $220-$240 million.
Acadia Healthcare Q2 Earnings Beat on Growing Admission Volumes
by Zacks Equity Research
ACHC beats Q2 earnings estimates despite lower average length of stay and higher expenses, thanks to increased patient days.
Healthcare: Winning Sector ETF Amid Soft U.S. July Jobs Report
by Sanghamitra Saha
Healthcare led July job gains with 55,000 new positions, as most other U.S. sectors showed little to no growth. Tap ETFs like XLV and VHT.
Are Options Traders Betting on a Big Move in HCA Healthcare Stock?
by Zacks Equity Research
Investors need to pay close attention to HCA Healthcare stock based on the movements in the options market lately.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
HUM Misses Q2 Earnings on Higher Benefit Costs, Ups '25 EPS View
by Zacks Equity Research
Humana's Q2 earnings fall year over year on a declining membership base. Notably, 2025 adjusted EPS is currently forecasted at around $17.00, up from the earlier view of around $16.25.
ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%
by Zacks Equity Research
Ensign Group's Q2 earnings improve 20.5% year over year, fueled by stronger occupancy, patient days and rental revenues.
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
by Zacks Equity Research
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
HCA Healthcare (HCA) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of +10.50% and +0.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why HCA Healthcare (HCA) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.